Drug intelligence / Profile preview

SHR-1909

Development stage: Phase 1
Lead developer: Shanghai Hengrui Pharmaceutical Co., Ltd.
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous (iv)

Overview

SHR-1909 is a novel fusion protein under development by Shanghai Hengrui Pharmaceutical for the treatment of cancers, specifically advanced malignant tumors. It is classified as an antineoplastic agent. The precise mechanism of action has not been publicly defined, and no specific molecular target has been disclosed in available sources. Clinical development is ongoing in China, with phase I trials evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor efficacy in patients with advanced cancer[1][2][5].

Other names: SHR 1909SHR1909SHR-1909SHR-A1909SHR-A-1909SHR-A 1909

Beyond the preview

Go deeper on SHR-1909.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1909.

Explore the full profile